Aurisco Pharmaceutical

Innovative pharmaceutical company established 1998 developing complex APIs, formulations, and CRDMO services in oligonucleotides, peptides, and GalNAc conjugation. Dedicated cGMP peptide manufacturing site in Yangzhou passed US FDA inspection in August 2023 (5 cGMP inspections passed in 2023: FDA/EU/PMDA/NMPA/KFDA) with multi-metric-ton GLP-1 capacity. Holds 18 active US DMFs including Semaglutide and Tirzepatide, plus 2 CEPs.

Directory assessment: Aurisco Pharmaceutical is listed as a manufacturer in the peptide supply chain, serving Asia markets from China (Yangzhou). As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. This profile lists 3 sources for reference. This supplier has a strong confidence score, indicating a high level of verification and reliability for B2B sourcing.